KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Restructuring Costs (2022 - 2024)

Historic Restructuring Costs for Neogenomics (NEO) over the last 3 years, with Q1 2024 value amounting to $2.4 million.

  • Neogenomics' Restructuring Costs fell 4880.44% to $2.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $8.8 million, marking a year-over-year decrease of 432.61%. This contributed to the annual value of $11.1 million for FY2023, which is 14552.7% up from last year.
  • Neogenomics' Restructuring Costs amounted to $2.4 million in Q1 2024, which was down 4880.44% from $1.2 million recorded in Q4 2023.
  • Over the past 5 years, Neogenomics' Restructuring Costs peaked at $4.7 million during Q1 2023, and registered a low of $1.2 million during Q4 2023.
  • Moreover, its 3-year median value for Restructuring Costs was $2.7 million (2023), whereas its average is $3.0 million.
  • As far as peak fluctuations go, Neogenomics' Restructuring Costs crashed by 7331.71% in 2023, and later plummeted by 4880.44% in 2024.
  • Neogenomics' Restructuring Costs (Quarter) stood at $4.5 million in 2022, then crashed by 73.32% to $1.2 million in 2023, then surged by 99.0% to $2.4 million in 2024.
  • Its last three reported values are $2.4 million in Q1 2024, $1.2 million for Q4 2023, and $2.1 million during Q3 2023.